论文部分内容阅读
Pancreatic cancer is one of the most highly aggressive and lethal of all solid malignancies.Systematically discovering and validatingnew biomarkers for early diagnosis of pancreatic cancer is under urgent demand.Targeted mass spectrometry (MS) through multiplereaction monitoring (MRM) has emerged as an alternative to affinity-based measurements of defined protein sets with faster andcost-efficient assay development,high sensitivity and high reproducibility.